Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh-160036, India.
Sci Rep. 2013;3:1445. doi: 10.1038/srep01445.
Cancer therapies are limited by the development of drug resistance, and mutations in drug targets is one of the main reasons for developing acquired resistance. The adequate knowledge of these mutations in drug targets would help to design effective personalized therapies. Keeping this in mind, we have developed a database "CancerDR", which provides information of 148 anti-cancer drugs, and their pharmacological profiling across 952 cancer cell lines. CancerDR provides comprehensive information about each drug target that includes; (i) sequence of natural variants, (ii) mutations, (iii) tertiary structure, and (iv) alignment profile of mutants/variants. A number of web-based tools have been integrated in CancerDR. This database will be very useful for identification of genetic alterations in genes encoding drug targets, and in turn the residues responsible for drug resistance. CancerDR allows user to identify promiscuous drug molecules that can kill wide range of cancer cells. CancerDR is freely accessible at http://crdd.osdd.net/raghava/cancerdr/
癌症治疗受到药物耐药性发展的限制，而药物靶点的突变是产生获得性耐药的主要原因之一。充分了解这些药物靶点的突变将有助于设计有效的个性化治疗方法。考虑到这一点，我们开发了一个名为“CancerDR”的数据库，该数据库提供了 148 种抗癌药物及其在 952 种癌细胞系中的药理学特征信息。CancerDR 提供了有关每个药物靶点的综合信息，包括：（i）天然变异序列，（ii）突变，（iii）三级结构，以及（iv）突变体/变体的比对谱。许多基于网络的工具已集成在 CancerDR 中。该数据库对于鉴定编码药物靶点的基因中的遗传改变以及负责耐药性的残基非常有用。CancerDR 允许用户识别能够杀死广泛范围癌细胞的混杂药物分子。CancerDR 可在 http://crdd.osdd.net/raghava/cancerdr/ 免费获取。
